Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes.
racial disparities
sickle cell disease
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
23
01
2023
received:
09
07
2022
accepted:
25
01
2023
medline:
5
4
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
Sickle cell disease mainly affects African Americans, and studies on racial differences in sickle cell disease outcomes are scanty. This study examined racial and ethnic differences in sickle cell disease prevalence, comorbidities, and outcomes. Using the National Inpatient Sample database from 2016 to 2018, we identified patients' records with a diagnosis of sickle cell disease using the International Classification of Diseases, Tenth Revision codes. The overall study population was further stratified by race into Blacks, Whites, and Hispanics. Using logistic regression, comorbidities and outcomes among sickle cell disease patients were compared between the three races/ethnicities. Of the 74 817 hospitalized for sickle cell disease, 69 889 (93.4%) were Blacks, 3603 (4.8%) were Hispanics, and 1325 (1.8%) were Whites. Compared to Whites, Blacks were more likely to have significantly higher odds of sickle cell crisis (odds ratio [OR]: 3.32; 95% confidence interval [CI]: 2.66-4.14) and blood transfusion (OR: 1.66; 95% CI: 1.37-2.02). There was no difference in mortality between Blacks and Whites. Compared to Hispanics, Blacks had significantly higher odds of sickle cell crisis (OR: 1.35; 95% CI: 1.19-1.53) and blindness (OR: 2.94; 95% CI: 1.22-7.11), lower odds of asplenia (OR: 0.57; 95% CI: 0.45-0.71) and gallstones (OR: 0.75; 95% CI: 0.58-0.95). However, Blacks had statistically significantly lower odds of mortality of 0.60 (95% CI: 0.38-0.93) than Hispanics. Prevalent sickle cell type, severity, complications, and comorbidities vary in different races. Physicians need to be aware of these differences to manage sickle cell patients efficiently. This study hopes to inform further research regarding the reasons for varying disease characteristics among racial groups and bridge a gap in tailored management protocols.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-563Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104. doi:10.1038/ncomms1104
Campbell AD, Colombatti R, Andemariam B, et al. An analysis of racial and ethnic backgrounds within the CASiRe international cohort of sickle cell disease patients: implications for disease phenotype and clinical research. J Racial Ethn Health Disparities. 2021;8(1):99-106. doi:10.1007/s40615-020-00762-2
Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(4 Suppl):S512-S521. doi:10.1016/j.amepre.2009.12.022
Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-78. doi:10.1002/ajh.21570
Paulukonis ST, Harris WT, Coates TD, et al. Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer. 2014;61(12):2271-2276. doi:10.1002/pbc.25208
Lim CS, Welkom JS, Cohen LL, Osunkwo I. Evaluating the protective role of racial identity in children with sickle cell disease. J Pediatr Psychol. 2012;37(8):832-842. doi:10.1093/jpepsy/jss059
Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell disease-related mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020;76(3 S):S28-S36. doi:10.1016/j.annemergmed.2020.08.009
CDC. What is Sickle Cell Disease? Centers for Disease Control and Prevention (CDC). Published August 18, 2022. Accessed January 23, 2023. https://www.cdc.gov/ncbddd/sicklecell/facts.html
Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB. Improving outcomes for patients with sickle cell disease in the United States: making the case for more resources, surveillance, and longitudinal data. JAMA Health Forum. 2021;2(10):e213467. doi:10.1001/jamahealthforum.2021.3467
Campbell A, Cong Z, Agodoa I, et al. The economic burden of end-organ damage among Medicaid patients with sickle cell disease in the United States: a population-based longitudinal claims study. J Manag Care Spec Pharm. 2020;26(9):1121-1129. doi:10.18553/jmcp.2020.20009
Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014;15(1):4-12. doi:10.1016/j.prrv.2013.11.003
Wang Y, Kennedy J, Caggana M, et al. Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. Genet Med Off J Am Coll Med Genet. 2013;15(3):222-228. doi:10.1038/gim.2012.128
HCUP-US NIS. Overview. Accessed January 23, 2023. https://www.hcup-us.ahrq.gov/nisoverview.jsp
Raffield LM, Ulirsch JC, Naik RP, et al. Common α-globin variants modify hematologic and other clinical phenotypes in sickle cell trait and disease. PLoS Genet. 2018;14(3):e1007293. doi:10.1371/journal.pgen.1007293
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;377(3):305. doi:10.1056/NEJMc1706325
Riley WJ. Health disparities: gaps in access, quality and affordability of medical care. Trans Am Clin Climatol Assoc. 2012;123:167-172. discussion 172-174.